Genzyme Recognizes Sixth Annual World MS Day - Company Supporting Wide Range of Programs to Help Improve the Lives of People Living with [...]
CHMP Adopts Positive Opinion for PLEGRIDY™ (Peginterferon Beta-1a) as a Treatment for Multiple Sclerosis in the European Union Friday, [...]
Opexa Reaches Enrollment Target in Phase IIb Trial of Personalized Immunotherapy for Secondary Progressive Multiple [...]
Teva announces COPAXONE® recognized as Brand of the Year by Pharmaceutical Executive Magazine JERUSALEM--(BUSINESS WIRE)--May 8, [...]
New TYSABRI® Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients Thursday, May 1, 2014 [...]
New Data Reinforce Efficacy of TECFIDERA® (Dimethyl Fumarate) in MS Patients with High Disease Activity Wednesday, April 30, 2014 7:30 [...]
Slowing of Brain Atrophy and Reductions in New Multiple Sclerosis Lesions Sustained at Three Years in Patients Treated with Genzyme’s [...]
Genzyme Announces Multi-Year Multiple Sclerosis Research Collaboration with Leading Academic Medical Center Wednesday, April 30, 2014 [...]
Teva Announces Supreme Court Denial of Request for Interim Relief to Stay Court of Appeals Ruling for Copaxone® Patent Due to the [...]
Biogen Idec to Present New Clinical Data from its Robust Neurology Portfolio at AAN Annual Meeting Monday, April 14, 2014 7:30 am [...]